# DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia

> **NCT06382168** · PHASE1,PHASE2 · RECRUITING · sponsor: **Delta-Fly Pharma, Inc.** · enrollment: 39 (estimated)

## Conditions studied

- Leukemia, Myeloid, Acute

## Interventions

- **DRUG:** DFP-10917
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT06382168
- **Lead sponsor:** Delta-Fly Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-12
- **Primary completion:** 2026-03-31
- **Final completion:** 2026-06-30
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2025-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06382168

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06382168, "DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06382168. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*